Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns  by Gartlan, Kate H. et al.
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a  b  s  t  r  a  c  t
Carbopol  is a  polyanionic  carbomer  used  in  man  for topical  application  and  drug  delivery  purposes.
However  parenteral  administration  of  Carbopol  in animal  models  results  in systemic  adjuvant  activ-
ity  including  strong  pro-inﬂammatory  type-1  T-cell  (Th1)  polarization.  Here  we investigated  potential
pathways  of  immune  activation  by Carbopol  by  comparison  with  other  well-characterized  adjuvants.
Carbopol  administration  triggered  rapid  and robust  leukocyte  recruitment,  pro-inﬂammatory  cytokine
secretion  and  antigen  capture  largely  by inﬂammatory  monocytes.  The  induction  of  antigen  speciﬁc  Th1
cells  by  Carbopol  was found  to occur via  a non-canonical  pathway,  independent  of MyD88/TRIF  signaling
and  in  the  absence  of pattern-recognition-receptor  (PRR)  activation  typically  associated  with  Th1/Ig2a
induction.  Using  multispectral  ﬂuorescence  imaging  (Imagestream)  and  electron  microscopy  we  demon-ntibodies
IV-1
strated  that  phagocytic  uptake  of Carbopol  particles  followed  by entry  into  the  phagosomal/lysosomal
pathway  elicited  conformational  changes  to the  polymer  and reactive  oxygen  species  (ROS)  production.
We  therefore  conclude  that  Carbopol  may  mediate  its  adjuvant  activity  via  novel  mechanisms  of  anti-
gen presenting  cell activation  and  Th1  induction,  leading  to enhanced  IgG2a  responses  independent  of
microbial  pattern  recognition.
©  2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Adjuvants are essential components of vaccines in which the
accine antigen lacks robust intrinsic immunogenicity, such as
hose composed of recombinant or puriﬁed subunits of pathogens,
r tumor antigens that may  require tolerance to be broken. In recent
ears the adjuvant ﬁeld has made breakthroughs in understanding
nderlying mechanisms of adjuvant activity, with the discovery
f multiple pattern recognition pathways triggering innate and
daptive immune activation [1,2]. This has led to the discovery
f numerous molecules with adjuvant activity that stimulate the
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immune system via deﬁned pathways, including those triggered
by toll-like receptors (TLRs) [1,2], the NLRP3 inﬂammasome [3,4]
and IRF3 [5,6]. Some of these molecules have made their way  into
clinical trials and have considerable promise in vaccine develop-
ment. Surprisingly, however, some of the most well-known and
longstanding adjuvants, including aluminum salts ‘alum’, oil-in-
water emulsions such as Freund’s adjuvants, and MF59 appear to
act by mechanisms at least partially distinct from these pathways
[7–9]. Other potential modes of adjuvant action are hypothesized
to include less speciﬁc activities such as the ‘depot’ effect by which
the adjuvant sequesters antigen and releases it into the system over
time, and local tissue damage resulting in release of intracellular
inﬂammatory mediators such as ATP, nucleic acids, uric acid, IL-25
and IL-33 [6,10].The immune-modulating activities of polyanions were ﬁrst
described over 30 years ago [11,12] and more recently, polyacrylic
acid polymers termed carbomers have been evaluated as adju-
vants in veterinary vaccines [13–18]. These reports suggest that
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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arbomers are not harmful in mammals and are more effective
han antigen alone. Carbopols have been combined with other adju-
ant formulations such as MF59 to yield additive or potentially
ynergistic adaptive immune responses [19,20], and Carbopol is
 component of the commercially-available adjuvant AdjuplexTM
Advanced BioAdjuvants) [21] and a licensed veterinary vaccine
n pigs (Suvaxyn, Wyeth). We  have previously demonstrated that
arbopol elicits strong Th1-type T and B-cell responses in mice,
ediating protection from otherwise lethal inﬂuenza infection, and
nti-tumor responses [22]. We  observed that Carbopol did not have
bvious toxicity in mice [22] or non-human primates [23], and pro-
ose that this type of polymer might have utility as a human vaccine
djuvant.
Here, we establish mechanistic insight into Carbopol’s adju-
ant effects, identifying strong inﬂammatory responses, cellular
ecruitment and phagocyte uptake of Carbopol, and identify phago-
ytosis as a key checkpoint in the immune response to Carbopol,
esulting in changes to the physical properties of the adjuvant
nd disruption of the lysosomal pathway. We  conclude that
arbopol utilizes a novel mechanism of APC activation in vivo
esulting in potent adaptive immune responses to co-administered
ntigen.
. Materials and methods
.1. Antigens, adjuvants and immunization
HIV-1 envelope glycoprotein (Env)-based recombinant solu-
le gp140 (<0.05 EU/mL endotoxin) was derived from HIV-197CN54
Polymun Scientiﬁc Inc.). Pre-conjugated ovalbumin (OVA)-AF647
Molecular Probes) was reconstituted in endotoxin-free PBS (Gibco)
rior to use. A 2% (w/v) Carbopol-974p stock (Particle Sciences Inc.,
K) was prepared from powder in endotoxin-free PBS, neutralized
o pH 7.2 with NaOH. Carbopol preparations contained <0.05 EU/mL
f endotoxin, assayed by Lonza Cologne GmbH. Alhydrogel adju-
ant (Brenntag Biosector) was diluted in endotoxin-free PBS prior
o injection. Balb/c, 129S6/SvEv and 129S6/SvEv.MyD88−/− mice
ere bred at the University of Oxford. C57BL/6, C57BL/6.NLRP3−/−
nd C57BL/6.Caspase1−/− mice were bred at Yale University.
57BL/6, C57BL/6.TRIF−/− and C57BL/6.MyD88−/−TRIF−/− mice
ere bred at The Fred Hutchinson Cancer Research Center. All
ice used in this study were age and sex-matched within each
xperiment and procedures were performed under the appropriate
icenses in accordance with the UK Animals (Scientiﬁc Procedures)
ct 1986 with local ethical approval.
.2. Leukocyte phenotyping
Peritoneal leukocytes were isolated by sequential small
2 mL)  and large (5 mL)  volume peritoneal lavages and super-
atant from small volume lavages used in cytokine/chemokine
nalyses. Cell fractions from both lavages were pooled and
nalyzed by ﬂow cytometry. The absolute numbers of B-
ells (CD11b−/intCD19+), T-cells (CD11b−CD3+), monocytes
CD11bhiLy6C++Ly6G−F4/80int), macrophages (CD11b+F4/80hi
y6G−Ly6C−), neutrophils (CD11b+Ly6GhiLy6C+F4/80−),
osinophils (CD11b+Ly6CloLy6GintF4/80loSSChi), and dendritic
ells (DC) (CD11b−/intCD11c+F4/80−/loMHC-IIhi) were determined.
o reduce non-speciﬁc antibody binding, cells were pre-incubated
n Mouse Fc-Block (BD Biosciences). Flow cytometry was  per-
ormed using either FACSCalibur (BD Biosciences) or CyAN ADP
ytometers (Beckmann Coulter, USA) and data analyzed via FloJo
oftware (TreeStar Inc., USA).4 (2016) 2188–2196 2189
2.3. Antibody/cytokine/chemokine detection
Serological analyses for antigen-speciﬁc antibodies were per-
formed as previously described [22]. Supernatants were separated
from either peritoneal lavage or cultured cells and cytokine con-
centrations determined via Bio-plex array (Bio-Rad Laboratories) or
ELISA (eBioscience). Analyses were performed following manufac-
turer’s instructions and cytokine concentrations calculated using
standard curves generated within the same assay. Antigen-speciﬁc
T-cell IFN secretion/accumulation was  assessed in splenocytes
cultured in the presence of gp140 (16 g/mL) over 3–5 days.
Secreted IFN was detected by ELISA (eBioscience) and the fre-
quencies of antigen speciﬁc IFN producing T-cells were detected
by IFN cytokine secretion assay (Miltenyi Biotec).
2.4. In vitro stimulation
Murine RAW-Blue and human THP-1-CD14-Blue (Invivogen)
reporter cells expressing NFB/AP-1 transcription factor-induced
embryonic alkaline phosphatase (SEAP) were used to detect PRR
stimulation. Cells were cultured for 24 h in the presence of PBS,
Carbopol or a variety of PRR ligands, supernatants harvested and
co-incubated with SEAP detection reagent Quantiblue (Invivogen).
Inﬂammasome activation was assessed after overnight incuba-
tion in the presence or absence of 25 ng/mL Escherichia coli LPS
(Sigma–Aldrich, USA), followed by extensive washing to remove
trace LPS prior to in vitro adjuvant stimulation (4 h, or (ATP) 30 min).
Supernatants were frozen and cells lysed in RIPA buffer (Life
Technologies) containing protease inhibitors. Lysates were directly
loaded in Laemmli buffer and gels semi-dry transferred to nitrocel-
lulose membranes (Amersham Biosciences, UK). Membranes were
blocked with 5% milk in PBS (Oxoid, UK) and caspase-1 detected
by polyclonal rabbit anti-caspase-1 antibody (Santa Cruz, USA) and
anti-rabbit IgG-HRP (Serotec, USA).
Please refer to the supplementary materials for additional meth-
ods.
3. Results
3.1. Carbopol triggers immune cell recruitment and potently
induces pro-inﬂammatory chemokines and cytokines
To investigate the potential mode of action of Carbopol,
we compared early innate immune responses induced by Car-
bopol with those induced by Alhydrogel, which elicits a strong
Th2/IgG1-associated immune bias [24]. Since cellular recruitment
is increasingly recognized as having a major inﬂuence on adju-
vanticity and adaptive immune outcome in response to adjuvants
[4,6,8,10,25–27], we  assessed Carbopol-induced chemokine and
cytokine secretion using the intraperitoneal (i.p.) administration
model. Although this does not represent a human immunization
route, it nevertheless represents a useful model for mechanis-
tic analysis [8,21]. Strong responses were detected in Carbopol
recipients (Fig. 1), with signiﬁcant induction of IL-1, IL-6, G-
CSF, KC, MIP-2, MCP-1 and RANTES (Fig. 1A–G). These chemokine
trends were shared by Alhydrogel-adjuvanted mice, which also
displayed signiﬁcant but less potent induction of IL-6, G-CSF, KC,
and MCP-1. One notable exception was the eosinophil recruit-
ment factor Eotaxin, secreted at high levels by Alhydrogel-treated
mice, but absent in Carbopol recipients (Fig. 1H). By contrast,
the pattern of cytokine secretion associated with T-cell polariza-
tion was  strikingly different between Carbopol and Alhydrogel
groups (Fig. 1I–K). Alhydrogel recipients expressed signiﬁcantly
elevated levels of the Th2-associated cytokines IL-4 and IL-5,
whereas Carbopol conversely elaborated signiﬁcant quantities
2190 K.H. Gartlan et al. / Vaccine 34 (2016) 2188–2196
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Fig. 1. Carbopol induces pro-inﬂammatory chemokines in vivo. (A–K) Groups of 4–5 Balb/c mice were injected i.p. with PBS, Carbopol (1 mg) or Alhydrogel (1 mg  Al3+)
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Collowed by a small volume peritoneal lavage at 4, 12 or 24 h. Cells were removed fro
y  multi-analyte proﬁling bead technology. Mean protein concentrations are shown
etermined by two-way ANOVA against PBS controls with Bonferroni correction (*
f the Th1-associated cytokine IL-12p40. Time course analyses
evealed differing kinetics within the response to Alhydrogel and
arbopol, with chemokines/cytokine concentrations peaking at 4 h
nd 12 h respectively.
We  next analyzed cellular recruitment post i.p. administration
Fig. 2A–H). Both Carbopol and Alhydrogel elicited a large inﬂux of
ells within 24 h, with signiﬁcant increases in neutrophil, monocyte
nd DC numbers, but striking differences were observed between
he two adjuvants. Of particular signiﬁcance were the high numbers
f monocytes but low numbers of eosinophils recruited into the
eritoneum of Carbopol-injected mice (Fig. 2C and H), compared
o the opposing phenotype in the Alhydrogel group. Alhydrogel
ecipients displayed a high degree of peritoneal eosinophilia and
igniﬁcantly lower numbers of monocytes compared to Carbopol
ecipients (p < 0.001). A decline in resident B cell and macrophage
umbers in the peritoneum is often associated with cellular acti-
ation (28) and this can be seen after 4 h in Alhydrogel treated
ice when compared to PBS controls (Fig. 2D–E). However, this
ffect was delayed in Carbopol-treated mice, in which mature
acrophage numbers were transiently increased 4 h after Carbopol
njection, prior to a signiﬁcant reduction at 24 h when compared to
BS treated control mice. These data suggest that whilst both Car-
opol and Alhydrogel drive signiﬁcant leukocyte recruitment and
nﬂammation early post-immunization, their mechanisms of action
re likely to be distinct.
.2. Carbopol promotes antigen uptake by APC
To investigate antigen uptake in the presence of Carbopol,
ice were injected with ﬂuorescently labeled ovalbumin (OVA)
ith or without adjuvant (Fig. 2I–J). 24 h later, antigen was
etected in association with multiple cell types, but principally
ith monocytes, macrophages and DC (Fig. 2I). Absolute numbers
f antigen-positive cells increased approximately ﬁve-fold with
arbopol or Alhydrogel (Fig. 2J). Despite similarities in the absolute
umber of antigen positive cells in the presence of either adju-
ant, uptake was biased toward distinct leukocyte populations:
arbopol drove antigen uptake primarily in monocytes, whereasage samples by centrifugation and peritoneal cytokine/chemokine titers quantiﬁed
. Dashed lines (where visible) represent the limit of detection and signiﬁcance was
5, **p < 0.01, ***p < 0.001).
Alhydrogel predominantly drove neutrophil uptake. Whilst dif-
ferences in monocyte-associated antigen uptake may reﬂect the
increased presence of monocytes in the Carbopol-stimulated mice,
the equal frequencies of neutrophils present in both groups sug-
gest additional bias toward antigen uptake by neutrophils in
Alhydrogel-stimulated mice. These data suggest there may  be dif-
fering mechanisms of antigen uptake induced by these adjuvants.
3.3. Carbopol drives Th1 responses in the absence of TLR
activation
Given that Th1-biased adaptive immunity is commonly
linked with adjuvants that drive pattern recognition recep-
tor (PRR), in particular TLR [28,29] activation, we  investigated
whether Carbopol might drive inﬂammation via this route using
monocyte/macrophage NFB/AP-1 reporter cell lines expressing
multiple PRRs. Whilst these cells responded to a variety of PRR lig-
ands, there was  no response to overnight culture with increasing
doses of Carbopol (Fig. 3A–C).
To conﬁrm this lack of PRR activation in vivo, mice deﬁ-
cient in expression of the TLR downstream signaling molecules
MyD88 and TRIF were immunized subcutaneously (s.c.) with HIV-1
gp140 alone or with Carbopol. Antigen-speciﬁc antibody responses
in TRIF−/− mice were unchanged, demonstrating that Carbopol
adjuvant activity does not require TRIF-dependent TLR activation
(Fig. 3D–F). By contrast, a signiﬁcant reduction in antigen-speciﬁc
IgG2c titers was observed in MyD88−/−TRIF−/− double-deﬁcient
mice immunized in the presence of Carbopol, resulting in a sig-
niﬁcant shift toward an IgG1 isotype bias. Since we had excluded
a requirement for TRIF signaling, we assessed antibody responses
to Carbopol in MyD88−/− mice in comparison with the TLR9 ligand
CpG and observed a similarly weak IgG2a response and IgG1 isotype
bias (Fig. 3G–I). It has been reported that MyD88 is also involved in
non-PRR signaling pathways including stabilization of IFN recep-
tor signaling [39] and B-cell immunoglobulin class switching [30].
We therefore directly assessed Carbopol-driven T-cell polariza-
tion in the absence of MyD88. To this end, IFN secretion (Fig. 3J)
and the frequency of antigen-speciﬁc IFN-secreting CD4+ T-cells
K.H. Gartlan et al. / Vaccine 34 (2016) 2188–2196 2191
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Fig. 2. Carbopol induces inﬂammatory cell recruitment and antigen uptake at the site of immunization. (A–H) Groups of 4–5 Balb/c mice were injected i.p. with PBS, Carbopol
(1  mg)  or Alhydrogel (1 mg  Al3+). Peritoneal lavages were performed after 4 and 24 h and leukocytes stained for ﬂow cytometry to determine the absolute numbers of
individual leukocyte populations. The mean absolute number of each population is shown ± SEM and signiﬁcance tested by two-way ANOVA against PBS controls with
Bonferroni correction. (I–J) Groups of 5 Balb/c mice were injected i.p. with PBS, Carbopol or Alhydrogel in the presence or absence of ovalbumin-Alexa-647 (OVA-A647) as
indicated. After 24 h, peritoneal lavages were performed and leukocytes identiﬁed by ﬂow cytometry. (I) The percentage of each population found associated with labeled
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y  Bonferroni correction (*p < 0.05, **p  < 0.01, ***p < 0.001).
Fig. 3K) were quantiﬁed in gp140-stimulated splenocytes isolated
rom immunized mice. Strikingly, unlike the TLR9 agonist CpG, Th1
olarization in response to Carbopol-adjuvanted immunization
as intact in the absence of MyD88. Therefore, reduced IgG2a-
iased humoral responses to Carbopol in the absence of MyD88
re not due to defective development of antigen-speciﬁc Th1 cells,
ut probably result from MyD88-dependent TLR-independent
ignaling pathways.
.4. Carbopol activates the inﬂammasome but its adjuvant
ctivity is independent of NLRP3 and Caspase 1
Inﬂammasome activation contributes to the adjuvant activ-
ty of Alhydrogel [26,31–33]. Since we observed signiﬁcant
ncreases in IL-1 secretion in response to Carbopol, which is a
ignature cytokine for inﬂammasome activation [4,8,34], we inves-
igated Carbopol-induced Caspase 1 maturation in vitro. Mature,
leaved Caspase-1 was detected in BMDM stimulated with either
arbopol or Alhydrogel, demonstrating dose-dependent inﬂam-
asome activation (Fig. 4A). However, no signiﬁcant differences
ere observed in antigen-speciﬁc IgG1 and IgG2a titers between
T,  inﬂammasome-deﬁcient NLRP3−/− and Caspase-1−/− miceepresent the mean ± SEM and signiﬁcance was  tested by one-way ANOVA followed
(Fig. 4B–D). These data suggest that although Carbopol is a potent
inﬂammasome activator, this pathway lacks a central role in driving
antigen-speciﬁc adaptive immunity in response to Carbopol.
3.5. Carbopol is captured and phagocytosed by antigen
presenting cells
Since charged particles are preferentially taken up by phago-
cytes including antigen presenting cells, we  investigated interac-
tions between leukocytes and Carbopol in vivo and in vitro (Fig. 5)
via covalently-conjugated ﬂuorescent Carbopol (Carbopol–AF488).
To control for any potential increase in cellular auto-ﬂuorescence or
uptake of residual unbound label (AF488), an unconjugated formu-
lation of Carbopol was  prepared containing equivalent quantities
of Carbopol and ﬂuorescent label (Carbopol + AF488). We  observed
signiﬁcant increases in Carbopol–AF488 positive cells within the
major phagocytic leukocyte populations of neutrophils, mono-
cytes, macrophages and DC (Fig. 5A–C) after i.p. administration.
To establish whether Carbopol–cell interactions represented Car-
bopol surface binding or internalization, we co-cultured BMDC
with Carbopol–AF488 in vitro and utilized high-throughput imag-
ing (Imagestream) (Fig. 5D). These analyses demonstrated that in
2192 K.H. Gartlan et al. / Vaccine 34 (2016) 2188–2196
Fig. 3. Carbopol adjuvanticity is independent of PRR signaling. NFB/AP-1 activation was measured in (A and B) RAW-Blue macrophages or (C) THP-1-CD14-Blue monocytes in
response to Carbopol or a range of PRR agonists ligands: TLR1/2 (Pam3CSK4, 100 ng/mL), TLR2 (LTA 100 ng/mL), TLR2/6 (FSL-1, 100 ng/mL), TLR3 (poly I:C 10 g/mL), TLR4 (LPS,
1  g/mL), TLR5 (Flagellin, 1 g/mL), TLR7/8 (Imiquimod, 5 g/mL), TLR9 (CpG, 1 g/mL), NOD1 (Tri-DAP, 10 g/mL), NOD2 (MDP, 10 g/mL), Dectin-1 (Zymosan, 100 g/mL)
and  RIG-I (CL075, 300 ng/mL). Histogram bars represent the mean NFB/AP-1 activation observed after 24 h stimulation pooled from n ≥ 5 independent experiments ± SD.
Signiﬁcance was tested by Kruskal–Wallis one-way ANOVA. (D–F) Groups of 5 WT,  TRIF−/− and MyD88−/−TRIF−/− mice were subcutaneously primed and boosted (week 4)
with  2 g gp140 alone or emulsiﬁed in Carbopol (1 mg). Serum endpoint titers of gp140-speciﬁc antibodies 2 weeks post-boost are shown for (D) IgG1, (E) IgG2c and (F) the
ratio  of log transformed IgG2a:IgG1 isotypes. (G–I) Groups of 5 WT and MyD88−/− mice were primed subcutaneously (s.c.) and boosted (week 3) with 5 g gp140 alone, or
in  the presence of Carbopol (1 mg)  or CpG-ODN (30 g). Serum endpoint titers of gp140-speciﬁc antibodies 2 weeks post-boost are shown for (G) IgG1, (H) IgG2a and (I) the
ratio  of log-transformed IgG2c:IgG1 isotypes. Bars represent mean endpoint titers ± SD, box and whiskers represent the median ± minimum to maximum values. Signiﬁcance
was  determined by one-way ANOVA with Bonferroni or Kruskal–Wallis analyses as described in materials and methods. (J–K) Groups of 4–5 WT or MyD88−/− mice were
immunized s.c. with either (J) 5 g gp140 alone or with Carbopol (0.5 mg)  or CpG-ODN (30 g), or (K) 2 g OVA alone or with Carbopol. Six weeks after immunization,
splenocytes were cultured with either (J) 16 g/mL gp140 or (K) 20 g/mL OVA for 5 days and IFN secretion measured by (J) cytokine ELISA or (K) ﬂow cytometry. Histogram
bars  represent the mean ± SD. Signiﬁcance was determined by one-way ANOVA with Bonferroni correction (*p < 0.05, **p < 0.01, ***p < 0.001, n.s. p > 0.05).
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Fig. 4. Carbopol adjuvant activity is independent of inﬂammasome activation. (A) Unstimulated or pre-stimulated (LPS 25 ng/mL) BMDM were incubated for 4 h with
increasing doses of Carbopol or Alhydrogel as indicated and mature Caspase-1 detected by Western blot. (B–D) Groups of 5 WT  (open bars), NLRP3−/− (hatched bars) and
C  g gp
a  log-tr
w eterm
>
i
5
c
n
a
F
f
a
p
b
b
a
aaspase1−/− (dark hatched bars) mice were primed and boosted s.c. (week 3) with 2
ntibodies 3 weeks post-boost are shown for (B) IgG1, (C) IgG2c and (D) the ratio of
hiskers represent the median ± minimum to maximum values. Signiﬁcance was  d
85% of Carbopol–AF488 positive cells the adjuvant was localized
ntracellularly and that the mean Carbopol particle diameter was
.2 m after phagocytosis (Fig. 5E–F). In many cases, individual
ells had phagocytosed multiple Carbopol particles, resulting in sig-
iﬁcant proportions of the intracellular space being occupied by the
djuvant.
ig. 5. Carbopol is captured by antigen presenting cells in vivo and in vitro. (A–C) Groups 
ree  ﬂuorescent label (Carbopol + AF488, control) or Carbopol covalently conjugated to ﬂ
nd  leukocytes identiﬁed by ﬂow cytometry. (A) Representative density plots showing in
opulation associated with labeled adjuvant and (C) the absolute numbers of adjuvant po
y  one-way ANOVA followed by Bonferroni correction (*p  < 0.05, **p < 0.01, ***p < 0.001). (
efore  surface (MHC-II) and nuclear (Hoechst) staining and Imagestream analysis. (D) Re
n  intracellular mask as described in materials and methods. Histogram representation o
nd  distribution of individual cell and Carbopol–AF488 particle diameters as measured b140 alone or mixed with Carbopol (1 mg). Serum endpoint titers of gp140-speciﬁc
ansformed IgG2a:IgG1 isotypes. Bars represent mean endpoint titers ± SD, box and
ined by one-way ANOVA with Bonferroni correction (n.s. p > 0.05).
3.6. Internalization into the phagolysosome promotes
conformational change in Carbopol and reactive oxygen species
productionGiven the minimally-biodegradable nature of Carbomers,
we examined the effects of Carbopol phagocytosis and the
of 4–5 Balb/c mice were injected i.p. with either unconjugated Carbopol (1 mg) and
uorescent-label (Carbopol–AF488). After 24 h, peritoneal lavages were performed
 vivo ﬂuorescent Carbopol uptake by phagocytes. (B) Percentage of each leukocyte
sitive cells. Histogram bars represent the mean ± SEM and signiﬁcance was tested
D–F) BMDC were cultured for 16 h in the presence of ﬂuorescently labeled Carbopol
presentative gallery of Carbopol positive cells determined by co-localization with
f (E) the frequency of BMDC with intracellular Carbopol–AF488 and (F) the mean
y Imagestream.
2194 K.H. Gartlan et al. / Vaccine 34 (2016) 2188–2196
Fig. 6. Carbopol drives ROS production in APC in a phagocytosis dependent manner. (A and B) BMDC were cultured for 16 h in the presence of ﬂuorescently-labeled Carbopol
followed by surface staining (MHC-II) and intracellular staining (Hoechst/EEA1/CD107a) prior to Imagestream analysis. Representative galleries of Carbopol positive cells
co-stained with (A) EEA1 or (B) CD107a are shown. (C and D) BMDC were cultured for 16 h in the presence of either Carbopol or TLR ligand-depleted Zymosan and imaged by
electron microscopy. (C) Representative SEM images of (i) extracellular Carbopol and (ii and iii) the early stages of Carbopol phagocytosis. (D) Representative TEM images of
(i  and ii) extracellular Carbopol, (iii and vi) phagocytosed Carbopol and (vii and viii) phagocytosed Zymosan. (E and F) ROS detection was  performed using Carboxy-H2DCFDA
labeling followed by spectrophotometer analysis at 525 nm.  (E) ROS production was assessed in BMDM cultured for 1, 2, or 24 h in the presence of either 1–100 g/mL
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iarbopol, 10 g/mL Zymosan or 10 M PMA. (F) ROS production was assessed in
resence  or absence of Cytochalasin D (10 M).
nsuing inﬂammatory response. Using high-throughput imaging
e assessed subcellular localization of Carbopol after phagocytic
ptake by BMDC (Fig. 6A and B). Carbopol particles did not co-
ocalize with the early-endosomal marker EEA1 [35], but were
redominantly located within CD107a+ lysosomal compartments
36]. Using electron microscopy we observed phagocytic cup
ormation and subsequent localization of Carbopol within compart-
ents with lysosomal morphology (Fig. 6C and D). Interestingly,
e observed substantial morphological modiﬁcations indicative of
onformational change in Carbopol within the lysosomal compart-
ent. Whereas extracellular Carbopol formed a very tightly packed
closed’ structure, lysosomal material adopted an ‘open’ mesh-like
onformation (Fig. 6Di-ii, iii-vi). It has been previously established
hat lysosomal accumulation of non-biodegradable particles and/or
ysosomal disruption can drive cellular activation and inﬂam-
ation, and a key signature of this response is ROS production
32,37]. We  therefore compared Carbopol-induced ROS production
n BMDC and BMDM in vitro with well-characterized particu-
ate and non-particulate controls (Fig. 6E and F). We  detected
igniﬁcant BMDM-derived ROS production in response to escalat-
ng concentrations of Carbopol, which increased in a dose- andC cultured for 4 h with either 100 g/mL Carbopol or 10 g/mL Zymosan in the
time-dependent manner (Fig. 6E). Signiﬁcant ROS production was
also induced by Carbopol exposure to BMDC, and this response
was completely abrogated by the presence of the actin polymer-
ization inhibitor Cytochalasin D, which prevented Carbopol uptake
(Fig. 6F). Taken together, these data suggest that phagocytosis
results in Carbopol accumulation and conformational modiﬁcation
within lysosomal compartments, triggering ROS production and
inﬂammation.
4. Discussion
The successful development of vaccines against pathogens
refractory to current vaccination strategies such as HIV-1, HCV and
Malaria will be partly dependent upon new adjuvant technolo-
gies [38]. Although Carbopol has been used in veterinary vaccines
for many years, the cellular mechanisms that drive its efﬁcacy in
adjuvant applications are yet to be characterized and therefore
investigation of the mode of action of Carbopol is warranted, par-
ticularly if this adjuvant is to be taken into man.
We demonstrate that Carbopol adjuvant activity is accompa-
nied by potent innate immune activation, comprising chemokine
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[18] Tollersrud T, Norstebo PE, Engvik JP, Andersen SR, Reitan LJ, Lund A. AntibodyK.H. Gartlan et al. / Va
nd pro-inﬂammatory cytokine secretion associated with rapid
eukocyte recruitment and antigen uptake. Striking differences
ere observed in early immune responses to Carbopol and Alhy-
rogel, consistent with the adaptive immune bias reported for
hese adjuvants [3,22]. Similar contrasting responses have been
eported between TLR and non-TLR adjuvants [39], suggesting that
he innate response to Carbopol more closely resembles that of
 TLR-targeted formulation. However, both in vitro and in vivo
nalyses demonstrated that Carbopol does not directly trigger TLR
ctivation and the downstream signaling pathways associated with
athogen recognition. In addition, Th1 induction was  intact in
he absence of TLR-Myd88/TRIF signaling, demonstrating a non-
anonical pathway of Carbopol-induced Th1 polarization. Whilst
he TLR-Myd88/TRIF signaling axis is the best characterized mech-
nism of Th1 induction, other pathways of APC activation and
esultant Th1-polarization have also been reported, particularly in
esponse to infection [7,40–42]. Although the alternate receptors
nd signaling pathways involved remain to be fully explored, some
on-TLR receptors such as C-type lectins (e.g. Mincle, MCL, Man-
ose receptor) and scavenger receptors can drive Th1 responses
ia both Myd88-dependent and -independent signaling [43–46].
iven the polyanionic structure of carbomers it is possible that
arbopol is recognized via one such pathway, which will require
urther investigation. Carbopol and Alhydrogel yield strikingly dif-
erent Th biases, with Carbopol and Alhydrogel eliciting robust Th1
nd Th2 responses respectively. We  demonstrate that these adap-
ive immune responses are mirrored by the early innate chemokine
nd cytokine responses that predict the adaptive immune out-
ome. Thus Carbopol selectively triggers MIP-2 MCP-1, RANTES
nd IL-12p40 release, whereas Alhydrogel drives rapid (within 4 h)
otaxin, IL-4 and IL-5 release.
As with other immune adjuvants, Carbopol efﬁciently induced
nﬂammasome formation. However since Carbopol-induced
umoral responses were independent of this process, we  conclude
hat inﬂammasome activation is secondary to other Carbopol-
riggered mechanisms of immune activation. Since it has been
eported that phagolysosomal destabilization after adjuvant
hagocytosis is an important step in inﬂammasome activation
32], we investigated the interactions between Carbopol and
hagocytes in more detail. Carbopol was avidly captured by
 range of phagocytes including APC, most likely due to its
articulate nature and strong negative charge which may  be
electively recognized by scavenger and other receptors on
hagocytes [47]. Uptake was accompanied by a conformational
hange in Carbopol structure similar to that described for a range
f homopolymers at low pH, including carbomers, which make
hese compounds suitable for controlled-release drug delivery
48]. Due to the polyanionic nature of Carbopol, a reduction in
H causes the carboxylate moieties on the polymer backbone
o lose charge, eliminating the repulsive electrostatic forces and
ollapsing the gel matrix. It is likely that the progressive acidi-
cation of the lysosome occurring during lysosomal maturation
49] drives the Carbopol conformational change. In addition,
nterference with lysosomal acidiﬁcation has been previously
eported in response to phagocytic uptake of polyanionic com-
ounds [50]. In line with this, we found a clear correlation between
arbopol phagocytosis and ROS production by APC, which is
 hallmark of lysosomal arrest and disruption. We  therefore
onclude that phagocytosis of the adjuvant plays an early and
ritical role in the ensuing inﬂammatory response to Carbopol
dministration.
The Th1 polarized response induced by Carbopol in the absence
f TLR stimulation is uncommon and warrants further investiga-
ion to understand the molecular mechanisms at play. Further work
n this type of adjuvant will elucidate mechanisms and lead the4 (2016) 2188–2196 2195
way to the design of adjuvants with increased potency and reduced
toxicity.
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